Noxopharm moves lupus skin therapy toward next human trial

Noxopharm will begin an extension clinical trial for SOF-SKN, a topical therapy targeting cutaneous lupus erythematosus, in Australia in early 2027 after completing a successful Phase I trial in healthy volunteers. The study aims to evaluate safety, tolerability, and initial efficacy signals to support Phase II planning targeted for 2028.

This Wire brief sits within Fusion42's coverage of Biotech.